Table 3.
Summary of AEs.
| | Q1/3W | Q2/3W | |||||
|---|---|---|---|---|---|---|---|
| TNBC (n = 15) | HR+/HER2−(n = 35) | NSCLC (n = 20) | TNBC (n = 11) | NSCLC (n = 9) | Ovarian (n = 3) | Pancreatic (n = 9) | |
| Any AE | 15 (100) | 35 (100) | 20 (100) | 11 (100) | 9 (100) | 3 (100) | 9 (100) |
| Any SAE | 7 (47) | 13 (37) | 9 (45) | 5 (45) | 4 (44) | 2 (67) | 5 (56) |
| Any treatment-related AE | 13 (87) | 29 (83) | 16 (80) | 9 (82) | 8 (89) | 2 (67) | 8 (89) |
| Led to treatment modificationa | 5 (33) | 8 (23) | 7 (35) | 6 (55) | 4 (44) | 0 | 2 (22) |
| Led to treatment discontinuation | 2 (13) | 2 (6) | 1 (5) | 0 | 2 (22) | 0 | 0 |
| Led to death | 0 | 2 (6) | 0 | 0 | 0 | 0 | 0 |
Data are n (%) of participants.
Abbreviations: Q1/3W, dosing on day 1 of repeated 21-day cycles; Q2/3W, dosing on days 1 and 8 of repeated 21-day cycles; SAE, serious AE.
a
Interruption or reduction in dose of study drug.